Evaluation of omega-3 in reduction of myocardal damage in patients with myocardial infarctions who undergoing streptokinase therapy

Phase 2

• Conditions: Myocardial Infarction.; Myocardial Infarction; I23-I25.8

• Registration Number: IRCT201402078307N5
• Lead Sponsor: Vice chancellor for research of Tabriz University of Medical Sciences.

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 22 February 2018

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

myocardial infarction patients; age 18-80; undergoing of thrombolytic therapy with streptokinase; filling of consent form.

Exclusion Criteria

Elevation of CK-MB and cTnI before injection of streptokinase; history of CABG during last three months; history of previous MI; renal dysfunction (creatinine above 2.5 mg/dl); contraindication of streptokinase therapy; acute MI; cardiogenic shock; Hypersensitivity to aspirin or clopidogrel or omega-3 and streptokinase injection.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
CK-MB level. Timepoint: Before, 8 and 24 hours after streptokinase injection. Method of measurement: ELISA kits.

Secondary Outcome Measures

Name	Time	Method
CTnI level. Timepoint: Before, 8 and 24 hours after streptokinase injection. Method of measurement: ELISA kits.